tbuckley/cabot-search huggingface dataset:
Gut microbiota regulate tumor metastasis via circRNA/miRNA networks
Authors: Zhuxian Zhu, Jianguo Huang, Xu Li, Jun Xing, Qiang Chen, Ruilin Liu, Feng Hua, Zhongmin Qiu, Yuanlin Song, Chunxue Bai, Yin-Yuan Mo, Ziqiang Zhang
Journal: Gut Microbes (2020)

Background Increasing evidence indicates that gut microbiota plays an important role in cancer progression. However, the underlying mechanism remains largely unknown. Here, we report that broad-spectrum antibiotics (ABX) treatment leads to enhanced metastasis by the alteration of gut microbiome composition.Methods Cancer LLC and B16-F10 cell metastasis mouse models, and microarray/RNA sequencing analysis were used to reveal the regulatory functions of microbiota-mediated circular RNA (circRNA)/microRNA (miRNA) networks that may contribute to cancer metastasis.Results The specific pathogen-free (SPF) mice with ABX treatment demonstrated enhanced lung metastasis. Fecal microbiota transplantation (FMT) from SPF mice or Bifidobacterium into germ-free mice significantly suppressed lung metastasis. Mechanistically, gut microbiota impacts circRNA expression to regulate levels of corresponding miRNAs. Specifically, such modulations of gut microbiota inhibit mmu_circ_0000730 expression in an IL-11-dependent manner. Bioinformatics analysis combined with luciferase reporter assays revealed reciprocal repression between mmu_circ_0000730 and mmu-miR-466i-3p. We further showed that both mmu-miR-466i-3p and mmu-miR-466 f-3p suppresses a number of genes involved in epithelial-mesenchymal transition (EMT) and stemness of cancer stem cells such as SOX9.Conclusions These results provide evidence of a previously unrecognized regulatory role of non-coding RNAs in microbiota-mediated cancer metastasis, and thus, the microbiome may serve as a therapeutic target.
2020 ACC Expert Consensus Decision Pathway on Management of Bleeding in Patients on Oral Anticoagulants
Authors: Gordon F. Tomaselli, Kenneth W. Mahaffey, Adam Cuker, Paul P. Dobesh, John U. Doherty, John W. Eikelboom, Roberta Florido, Ty J. Gluckman, William J. Hucker, Roxana Mehran, Steven R. Messé, Alexander C. Perino, Fatima Rodriguez, Ravindra Sarode, Deborah M. Siegal, Barbara S. Wiggins
Journal: Journal of the American College of Cardiology (2020)
FGFR3 Mutation Status and FGFR3 Expression in a Large Bladder Cancer Cohort Treated by Radical Cystectomy: Implications for Anti-FGFR3 Treatment?†
Authors: Bas W.G. van Rhijn, Laura S. Mertens, Roman Mayr, Peter J. Bostrom, Francisco X. Real, Ellen C. Zwarthoff, Joost L. Boormans, Cheno Abas, Geert J.L.H. van Leenders, Stefanie Götz, Katrin Hippe, Simone Bertz, Yann Neuzillet, Joyce Sanders, Annegien Broeks, Michiel S. van der Heijden, Michael A.S. Jewett, Mirari Marquez, Robert Stoehr, Alexandre R. Zlotta, Markus Eckstein, Yanish Soorojebally, Hossain Roshani, Maximilian Burger, Wolfgang Otto, François Radvanyi, Nanor Sirab, Damien Pouessel, Bernd Wullich, Theo H. van der Kwast, Núria Malats, Arndt Hartmann, Yves Allory, Tahlita C.M. Zuiverloon
Journal: European Urology (2020)
THU0228 Prevalence of hepatitis e virus in behÇet’s disease
Authors: Ý Ertenli, S Kiraz, S Apras, MA Oztürk, V Çobankara, Z Balkancý, M Çalgüner
Journal: Annals of the Rheumatic Diseases (2001)

<h3>Background</h3> Behçet's disease (BD) is a multisystem disorder originally described by the Turkish dermatologist Hulusi Behçet. Although its aetiology is unknown, vasculitis is widely accepted as the underlying pathological process. Viral infections, especially hepatitis B and C viruses, have been proposed to be triggering factors via soluble immune complexes in vasculitic syndromes. Viral aetiology has also been postulated in the etiopathogenesis of BD. A possible association of Hepatitis C virus have been investigated previously, but no definite relationship has been found. More recently, serological evidences of previous Hepatitis A, Hepatitis C and Hepatitis E virus infections were found to be similar between Behçet's patients and control group. <h3>Objectives</h3> In this cross-sectional study we aimed to investigate the prevalence of Hepatitis E virus (HEV), which is the major cause of non-parenteral non-A non-B hepatitis, in our group of patients with BD. <h3>Methods</h3> Sixty-four patients (22 female, 42 male, mean age: 39, min-max: 16–68) were enrolled in this study. Clinical and demographical characteristics of our study group were given in table. Hepatitis E antigen was studied in serum of patients using commercial kits (International Immuno-Diagnostics, USA). <h3>Results</h3> Seropositivity for HEV was detected in 3 patients (4.69%). This result is comparable to previous report of seroprevelance of HEV in Turkish population (5.9%). <h3>Conclusion</h3> We concluded that HEV does not seem to have a place in the etiopathogenesis of BD, at least in our population.
Low prevalence of active COVID-19 in Slovenia: a nationwide population study of a probability-based sample
Authors: P. Maver Vodičar, A. Oštrbenk Valenčak, B. Zupan, T. Avšič Županc, S. Kurdija, M. Korva, M. Petrovec, J. Demšar, N. Knap, E. Štrumbelj, V. Vehovar, M. Poljak
Journal: Clinical Microbiology and Infection (2020)
NEDD8活性酵素阻害剤MLN4924は,びまん性大細胞型B細胞リンパ腫モデルにおいて活性がある:NF-κB依存性リンパ腫治療の理論的説明 | 文献情報 | J-GLOBAL 科学技術総合リンクセンター
Authors: A Milhollen Michael, Traore Tary, Adams-Duffy Jennifer, P Thomas Michael, J Berger Allison, Dang Lenny, R Dick Lawrence, J Garnsey James, Koenig Erik, P Langston Steven, Manfredi Mark, Narayanan Usha, Rolfe Mark, M Staudt Louis, A Soucy Teresa, Yu Jie, Zhang Julie, B Bolen Joseph, G Smith Peter
Journal: Blood (2010)
Survival outcomes and clinical benefit in patients with acute myeloid leukemia treated with glasdegib and low-dose cytarabine according to response to therapy
Authors: Jorge E. Cortes, Florian H. Heidel, Walter Fiedler, B. Douglas Smith, Tadeusz Robak, Pau Montesinos, Anna Candoni, Brian Leber, Mikkael A. Sekeres, Daniel A. Pollyea, Roxanne Ferdinand, Weidong Wendy Ma, Thomas O’Brien, Ashleigh O’Connell, Geoffrey Chan, Michael Heuser
Journal: Journal of Hematology & Oncology (2020)

Abstract Background The phase 2 BRIGHT AML 1003 trial evaluated efficacy and safety of glasdegib + low-dose cytarabine (LDAC) in patients with acute myeloid leukemia ineligible for intensive chemotherapy. The multicenter, open-label study randomized patients to receive glasdegib + LDAC ( n = 78) or LDAC alone ( n = 38). The rate of complete remission (CR) was 19.2% in the glasdegib + LDAC arm versus 2.6% in the LDAC arm ( P = 0.015). Methods This post hoc analysis determines whether the clinical benefits of glasdegib are restricted to patients who achieve CR, or if they extend to those who do not achieve CR. Results In patients who did not achieve CR, the addition of glasdegib to LDAC improved overall survival (OS) versus LDAC alone (hazard ratio = 0.63 [95% confidence interval, 0.41–0.98]; P = 0.0182; median OS, 5.0 vs 4.1 months). Additionally, more patients receiving glasdegib + LDAC achieved durable recovery of absolute neutrophil count (≥ 1000/μl, 45.6% vs 35.5%), hemoglobin (≥ 9 g/dl, 54.4% vs 38.7%), and platelets (≥ 100,000/μl, 29.8% vs 9.7%). Transfusion independence was achieved by 15.0% and 2.9% of patients receiving glasdegib + LDAC and LDAC alone, respectively. Conclusions Collectively, these data suggest that there are clinical benefits with glasdegib in the absence of CR. Trial registration ClinicalTrials.gov NCT01546038 (March 7, 2012)
Point-of-Care Spirometry Identifies High-Risk Individuals Excluded from Lung Cancer Screening
Authors: Andrew C. L. Lam, Reenika Aggarwal, Jingyue Huang, Robert Varadi, Lori Davis, Ming Sound Tsao, Frances A. Shepherd, Stephen Lam, John Kavanagh, Geoffrey Liu
Journal: American Journal of Respiratory and Critical Care Medicine (2020)
Response to: ‘Riociguat in systemic sclerosis: a potential for disease modification’ by Jain and Dhir
Authors: Dinesh Khanna, Oliver Distler
Journal: Annals of the Rheumatic Diseases (2020)

We thank Drs Jain and Dhir for their comments 1 regarding our recent article in Annals of the Rheumatic Diseases entitled 'Riociguat in patients with early diffuse cutaneous systemic sclerosis (RISE-SSc): randomised, double-blind, placebo-controlled multicentre trial'. 2 We agree that forced vital capacity (FVC) in millilitres, as in the Safety and Efficacy of Nintedanib in Systemic Sclerosis (SENSCIS) trial, 3 may be informative, and that the effects of riociguat on swollen and tender joints are also of interest.We present below (table 1) the results from RIociguat Safety and Efficacy in patients with diffuse cutaneous Systemic Sclerosis (RISE-SSc) for FVC in millilitres for the overall population and for patients with interstitial lung disease (ILD) at baseline according to medical history.The results are broadly consistent with those reported for FVC%. 2 In view of the small sample sizes, a statistical analysis was not performed for the ILD subgroup.Data for total swollen joint scores and total tender joint scores are also shown.As the primary endpoint was not met, these data are purely descriptive and differences between the study arms cannot be considered statistically significant.Data on tenosynovitis were not captured, and radiography was not routinely performed in the RISE-SSc study.Data on biomarkers including high-sensitivity C-reactive protein will be published as a separate paper.
Multidisciplinary care of epidermolysis bullosa during the COVID-19 pandemic—Consensus: Recommendations by an international panel of experts
Authors: Dedee F. Murrell, Anne W. Lucky, Julio C. Salas-Alanis, David T. Woodley, Francis Palisson, Ken Natsuga, Milos Nikolic, Mae Ramirez-Quizon, Amy S. Paller, Irene Lara-Corrales, Mohammadreza Amir Barzegar, Eli Sprecher, Cristina Has, Martin Laimer, Anna L. Bruckner, Asli Bilgic, Arti Nanda, Diana Purvis, Alain Hovnanian, Slobodna Murat-Sušić, Johannes Bauer, Johannes S. Kern, Christine Bodemer, Linda K. Martin, Jemima Mellerio, Cezary Kowaleski, Susan J. Robertson, Leena Bruckner-Tuderman, Elena Pope, M. Peter Marinkovich, Jean Y. Tang, John Su, Jouni Uitto, Lawrence F. Eichenfield, Joyce Teng, Mark Jean Aan Koh, Sang Eun Lee, Phuong Khuu, Heather I. Rishel, Mette Sommerlund, Karen Wiss, Chao-Kai Hsu, Tor Wo Chiu, Anna E. Martinez
Journal: Journal of the American Academy of Dermatology (2020)
Evaluation of Metagenomic Deep Sequencing as a Diagnostic Test for Infectious Keratitis
Authors: Prajna Lalitha, N. Venkatesh Prajna, Misra Sikha, Rameshkumar Gunasekaran, Armin Hinterwirth, Lee Worden, Cindi Chen, Lina Zhong, Zijun Liu, Thomas M. Lietman, Gerami D. Seitzman, Thuy Doan
Journal: Ophthalmology (2020)
Outcomes of Bilateral Cataract Surgery in Infants 7 to 24 Months of Age Using the Toddler Aphakia and Pseudophakia Treatment Study Registry
Authors: Erick D. Bothun, M. Edward Wilson, Kimberly G. Yen, Jill S. Anderson, Natalie C. Weil, Allison R. Loh, David Morrison, Sharon F. Freedman, David A. Plager, Deborah K. Vanderveen, Elias I. Traboulsi, David O. Hodge, Scott R. Lambert
Journal: Ophthalmology (2020)
Cardiovascular Determinants of Aerobic Exercise Capacity in Adults With Type 2 Diabetes
Authors: Gaurav S. Gulsin, Joseph Henson, Emer M. Brady, Jack A. Sargeant, Emma G. Wilmot, Lavanya Athithan, Zin Z. Htike, Anna-Marie Marsh, John D. Biglands, Peter Kellman, Kamlesh Khunti, David Webb, Melanie J. Davies, Thomas Yates, Gerry P. McCann
Journal: Diabetes Care (2020)

To assess the relationship between subclinical cardiac dysfunction and aerobic exercise capacity (peak VO2) in adults with type 2 diabetes (T2D), a group at high risk of developing heart failure.Cross-sectional study. We prospectively enrolled a multiethnic cohort of asymptomatic adults with T2D and no history, signs, or symptoms of cardiovascular disease. Age-, sex-, and ethnicity-matched control subjects were recruited for comparison. Participants underwent bioanthropometric profiling, cardiopulmonary exercise testing, and cardiovascular magnetic resonance with adenosine stress perfusion imaging. Multivariable linear regression analysis was undertaken to identify independent associations between measures of cardiovascular structure and function and peak VO2.A total of 247 adults with T2D (aged 51.8 ± 11.9 years, 55% males, 37% black or south Asian ethnicity, HbA1c 7.4 ± 1.1% [57 ± 12 mmol/mol], and duration of diabetes 61 [32-120] months) and 78 control subjects were included. Subjects with T2D had increased concentric left ventricular remodeling, reduced myocardial perfusion reserve (MPR), and markedly lower aerobic exercise capacity (peak VO2 18.0 ± 6.6 vs. 27.8 ± 9.0 mL/kg/min; P < 0.001) compared with control subjects. In a multivariable linear regression model containing age, sex, ethnicity, smoking status, and systolic blood pressure, only MPR (β = 0.822; P = 0.006) and left ventricular diastolic filling pressure (E/e') (β = -0.388; P = 0.001) were independently associated with peak VO2 in subjects with T2D.In a multiethnic cohort of asymptomatic people with T2D, MPR and diastolic function are key determinants of aerobic exercise capacity, independent of age, sex, ethnicity, smoking status, or blood pressure.
Natriuretic Peptide Levels After Transcatheter Aortic Valve Replacement
Authors: Robert O. Bonow, Patrick T. O’Gara
Journal: JAMA Cardiology (2020)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Cardiology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Cardiology journal
Characteristics and outcomes of health and social care workers testing positive for SARS-CoV-2 in the Tayside region of Scotland
Authors: Moneeza K. Siddiqui, Benjamin Parcell, Sarah Allstaff, Colin Palmer, James D. Chalmers, Samira Bell
Journal: European Respiratory Journal (2020)

<b>Tayside, Scotland was one of the first health boards to institute testing for all symptomatic workers. As expected, there was a high prevalence of SARS-CoV-2 among health and social care workers; however, in most cases disease was mild.</b>https://bit.ly/38JaUmB
Refining amyloid complete hematological response: Quantitative serum free light chains superior to ratio
Authors: Eli Muchtar, Morie A. Gertz, Martha Q. Lacy, Nelson Leung, Francis K. Buadi, David Dingli, Suzanne R. Hayman, Ronald S. Go, Prashant Kapoor, Wilson Gonsalves, Taxiarchis V. Kourelis, Rahma Warsame, Yi Lisa Hwa, Amie Fonder, Miriam Hobbs, Stephen Russell, John A. Lust, Mustaqeem Siddiqui, S. Vincent Rajkumar, Robert A. Kyle, Shaji K. Kumar, Angela Dispenzieri
Journal: American Journal of Hematology (2020)

Abstract Response assessment in light chain (AL) amyloidosis is based on serum and urine monoclonal protein studies. Newly diagnosed patients (n = 373) who achieved very good partial response or complete response (CR) to first line therapy were assessed for the survival impact of each of the monoclonal protein studies. At end of therapy (EOT), negative serum/urine immunofixation (IFE) was achieved in 61% of patients, 72% achieved normal serum free light chain ratio (sFLCR), and the median involved free light chain (iFLC) and difference between involved to uninvolved light chain (dFLC) were 17 mg/L and 5 mg/L, respectively. Overall, 46% of patients achieved a CR at EOT. At EOT, iFLC ≤20 mg/L and dFLC ≤10 mg/L were additive in survival discrimination to negative serum/urine IFE and were independent predictors of overall survival. In contrast, normalization of sFLCR did not add survival discrimination to serum/urine IFE and was not independent predictor of survival. We propose a new definition for hematological CR to include serum/urine IFE negativity plus iFLC ≤20 mg/L or dFLC ≤10 mg/L, instead of the current definition of serum/urine IFE negativity and normal sFLCR. Complete response using dFLC ≤10 mg/L had the best performance in those with significant renal dysfunction and by light chain isotype, making it the preferred partner to IFE. Validation of these results in a multicenter cohort is warranted.
THU0244 Cross-sectional study of osteoarthritis in some native populations of russia
Authors: LI Alexeeva, S Erdesz, NM Mylov, AV Smirnov, LI Benevolenskaya
Journal: Annals of the Rheumatic Diseases (2001)

<h3>Background</h3> <h3>Objectives</h3> To study the prevalence of knee and hand osteoarthritis (OA) in Ugro-Finnish populations of Russia. <h3>Methods</h3> We examined by cross-sectional epidemiological methods three populations from Russian Ugro-Finnish language family: Erzya (E), Moksha (Mo), Marij (Ma). Using standard questionary we examined 1312 rural residents aged 15 yrs and over (representativit &gt;80%). Knee and hand OA was diagnosed by using ACR criteria. Films were readed using Kellgren-Lawrence scales. <h3>Results</h3> 339 from 1312 had knee joint pain. The prevalence of knee OA was 11,2% in E, 12,5% in Mo, 8,1% in Ma in individuals aged over 15 and 14,1%, 23,8%, 14,4% accordingly in individuals aged over 50. 212 from 1312 had hand joint pain. Hand OA was diagnosed in 10,0% E, in 3,7% Mo and in 3,8% Ma. The prevalence of hand OA increased with age: 19,8%, 12,2%, 13,5% accordingly in individuals aged over 60. Knee and hand OA were more higher among women than men. <h3>Conclusion</h3> These data demonstrate that knee and hand OA is widespread in Ugro-Finnish populations especially in individuals aged over 50. The ACR criteria for hand and knee OA may be used in population studies.
Microbiome-induced antigen-presenting cell recruitment coordinates skin and lung allergic inflammation
Authors: Niki D. Ubags, Aurélien Trompette, Julie Pernot, Britt Nibbering, Nicholas C. Wong, Céline Pattaroni, Alexis Rapin, Laurent P. Nicod, Nicola L. Harris, Benjamin J. Marsland
Journal: Journal of Allergy and Clinical Immunology (2020)
Repeated false-negative tests delayed diagnosis of COVID-19 in a case with granulomatosis with polyangiitis under maintenance therapy with rituximab and concomitant influenza pneumonia
Authors: Samy Hakroush, Jonas Franz, Jörg Larsen, Peter Korsten, Martin Sebastian Winkler, Björn Tampe
Journal: Annals of the Rheumatic Diseases (2020)

Background/Aim: The significance of the anatomical variations of proximal jejunal vein [the so-called 1st jejunal vein (J1v)] has been reported from a technical standpoint. The aim of this study was to retrospectively investigate the prognostic impact of the anatomical variations of J1v in the surgical treatment of resectable pancreatic cancer (PC). Patients and Methods: A total of 49 patients with resectable PC located in the uncinate process were included in this study. The J1v converging pattern was divided into 2 groups in terms of its relation to the SMA (i.e., the J1v status): i) group D: the J1v travels posterior to the SMA; ii) group V: the J1v travels anterior to the SMA. The associations between the J1v status and surgical outcome were assessed. Results: The 5-year survival rate after resection in group V (35%) was significantly lower than that in group D (70%) (p=0.029), and the J1v status of group V was the only independent negative prognostic factor (HR=5.49; 95% CI=1.69-19.3; p=0.005). Conclusion: The J1v converging pattern is a significant prognostic variable in patients with PC located in the uncinate process: the J1v status of group V was significantly associated with impaired survival.
Association of Natriuretic Peptide Levels After Transcatheter Aortic Valve Replacement With Subsequent Clinical Outcomes
Authors: Jared M. O’Leary, Marie-Annick Clavel, Shmuel Chen, Kashish Goel, Brian O’Neill, Sammy Elmariah, Aaron Crowley, Maria C. Alu, Vinod H. Thourani, Martin B. Leon, Philippe Pibarot, Brian R. Lindman
Journal: JAMA Cardiology (2020)

Among those with aortic stenosis, natriuretic peptide levels can provide risk stratification, predict symptom onset, and aid decisions regarding the timing of valve replacement. Less is known about the prognostic significance and potential clinical utility of natriuretic peptide levels measured after valve replacement.To determine the associations of elevated B-type natriuretic peptide (BNP) levels after transcatheter aortic valve replacement (TAVR) and change in BNP levels between follow-up time points with risk of subsequent clinical outcomes.In this cohort study, patients with severe symptomatic aortic stenosis at intermediate, high, or prohibitive surgical risk for aortic valve replacement who underwent TAVR from the PARTNER IIA cohort, PARTNER IIB cohort, SAPIEN 3 intermediate-risk registry, and SAPIEN 3 high-risk registry were included. B-type natriuretic peptide levels were obtained at baseline and discharge as well as 30 days and 1 year after TAVR. For each measurement, a BNP ratio was calculated using measured BNP level divided by the upper limit of normal for the assay used. Outcomes were evaluated in landmark analyses out to 2 years. Data were collected from April 2011 to January 2019.All-cause death, cardiovascular death, rehospitalization, and the combined end point of cardiovascular death or rehospitalization.Among 3391 included patients, 1969 (58.1%) were male, and the mean (SD) age was 82 (7.5) years. Most patients had a BNP ratio greater than 1 at each follow-up time point, including 2820 of 3256 (86.6%) at baseline, 2652 of 2995 (88.5%) at discharge, 1779 of 2209 (80.5%) at 30 days, and 1799 of 2391 (75.2%) at 1 year. After adjustment, every 1-point increase in BNP ratio at 30 days (approximately equivalent to an increase of 100 pg/mL in BNP) was associated with an increased hazard of all-cause death (adjusted hazard ratio [aHR], 1.11; 95% CI, 1.07-1.15), cardiovascular death (aHR, 1.16; 95% CI, 1.11-1.21), and rehospitalization (aHR, 1.08; 95% CI, 1.03-1.14) between 30 days and 2 years. Among those with a BNP ratio of 2 or more at discharge, after adjustment, every 1-point decrease in BNP ratio between discharge and 30 days was associated with a decreased hazard of all-cause death (aHR, 0.92; 95% CI, 0.88-0.96) between 30 days and 2 years.Elevated BNP levels after TAVR was independently associated with increased subsequent mortality and rehospitalizations. Further studies to determine how best to mitigate this risk are warranted.
Effect of delays in the 2-week-wait cancer referral pathway during the COVID-19 pandemic on cancer survival in the UK: a modelling study
Authors: Amit Sud, Bethany Torr, Michael E Jones, John Broggio, Stephen Scott, Chey Loveday, Alice Garrett, Firza Gronthoud, David L Nicol, Shaman Jhanji, Stephen A Boyce, Matthew Williams, Elio Riboli, David C Muller, Emma Kipps, James Larkin, Neal Navani, Charles Swanton, Georgios Lyratzopoulos, Ethna McFerran, Mark Lawler, Richard Houlston, Clare Turnbull
Journal: The Lancet Oncology (2020)